Dr. McDermott on the Role of VEGF Targeted Therapy in RCC
David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma.
David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma (RCC).
For most newly diagnosed patients, the standard of care is a VEGF-targeted agent, as clear cell kidney cancers are very VEGF driven, McDermott says.
Many patients end up developing resistance though—at least half within the first year—suggesting the need for the development of new therapies in this setting.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
